Prof Loibl speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about results from Gepar Nuevo, a trial of anthracycline chemotherapy with durvalumab as a treatment for patients with triple negative breast...
Original Article: Chemotherapy plus durvalumab in triple negative breast cancer